![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Merck Launches Herceptin Biosimilar Ontruzant
Merck Launches Herceptin Biosimilar Ontruzant
Merck has launched its Herceptin biosimilar Ontruzant (rastuzumab-dttb) in the U.S., priced 15 percent lower than Roche’s blockbuster cancer drug.
Merck is launching the product at a wholesale cost of $1,325 for the 150 mg single-dose vial and $3,709 for the 420 mg multiple-dose vial.
The FDA approved Ontruzant in January 2019, based on data demonstrating that it is highly similar to its reference product.
Upcoming Events
-
21Oct